Adefovir dipivoxil (Synonyms: 阿德福韦酯; GS 0840)

目录号: HY-B0255 纯度: 99.03%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Adefovir dipivoxil 是一种腺苷类似物，是核苷逆转录酶 (nucleoside reverse transcriptase) 抑制剂 Adefovir 的口服前体。Adefovir dipivoxil 对 Lamivudine 耐药株和野生型菌株均有抑制作用。Adefovir dipivoxil 具有抗正痘病毒活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Adefovir dipivoxil Chemical Structure

CAS No. : 142340-99-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥567	In-stock
50 mg	￥515	In-stock
100 mg	￥884	In-stock
500 mg	￥1750	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Adefovir dipivoxil:

Adefovir dipivoxil (Standard) 询价

MCE 顾客使用本产品发表的 1 篇科研文献

•Int J Mol Med. 2019 Jun;43(6):2491-2498. [Abstract]

Adefovir dipivoxil 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Adefovir dipivoxil, an adenosine analogue, is an oral proagent of the nucleoside reverse transcriptase inhibitor Adefovir. Adefovir dipivoxil inhibits both the wild type and HBV Lamivudine-resistant strains^[1]^[2]. Adefovir dipivoxil shows anti-orthopoxvirus activity.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CCRF-CEM	EC₅₀	0.045 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 23603046]
CCRF-CEM	EC₅₀	0.062 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 23603046]
HEK293	IC₅₀	13.5 μM Compound: ADV	Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method	[PMID: 31301948]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	4 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HepG2 2.2.15	CC₅₀	> 400 μM Compound: ADV	Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay	[PMID: 27458783]
HepG2 2.2.15	IC₅₀	0.33 μM Compound: 2	Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR	[PMID: 19889538]
HepG2 2.2.15	IC₅₀	0.48 μM Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	IC₅₀	0.58 μM Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	EC₅₀	0.96 μM Compound: 1	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis	[PMID: 22305613]
HepG2 2.2.15	EC₅₀	1.5 μM Compound: ADV	Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	1.8 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2.1 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2.2 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	CC₅₀	438.92 μM Compound: ADV	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay	[PMID: 31301948]
HepG2 2.2.15	EC₅₀	7.5 μM Compound: ADV	Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HK-2	CC₅₀	488.05 μM Compound: 1	Cytotoxicity against human HK2 cells by MTT assay Cytotoxicity against human HK2 cells by MTT assay	[PMID: 22305613]
Huh-7	EC₅₀	0.83 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HBV transfected in human HuH7 cells assessed as reduction of viral DNA level after 7 days by qPCR analysis Antiviral activity against wild type HBV transfected in human HuH7 cells assessed as reduction of viral DNA level after 7 days by qPCR analysis	[PMID: 23603046]
Huh-7	EC₅₀	1.5 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	14 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2 μM Compound: Adefovir dipivoxil	Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.4 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.5 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.6 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Vero	IC₅₀	0.6 μM Compound: 10a	Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro	[PMID: 8021925]
WI-38	EC₅₀	0.7 μM Compound: PMEA dipivoxil	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]
WI-38	CC₅₀	3.1 μM Compound: PMEA dipivoxil	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]

Clinical Trial

分子量

501.47

Formula

C₂₀H₃₂N₅O₈P

CAS 号

142340-99-6

性状

固体

颜色

White to off-white

中文名称

阿德福韦酯

结构分类

Others

初始来源

内源性代谢物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (199.41 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 0.67 mg/mL (1.34 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9941 mL	9.9707 mL	19.9414 mL
5 mM	0.3988 mL	1.9941 mL	3.9883 mL
10 mM	0.1994 mL	0.9971 mL	1.9941 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.99 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.99 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.99 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.03%

选择批次：

Data Sheet (629 KB) SDS (393 KB)

COA (291 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Noble S, et al. Adefovir dipivoxil. Drugs. 1999;58(3):479-489. [Content Brief]

[2]. Buti M, et al. Adefovir dipivoxil. Drugs Today (Barc). 2003;39(2):127-135. [Content Brief]

[3]. Mark N Prichard, et al. Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord. 2005 Mar;5(1):17-28. [Content Brief]

Adefovir dipivoxil 相关分类

Infection Cancer

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.9941 mL	9.9707 mL	19.9414 mL	49.8534 mL
DMSO	5 mM	0.3988 mL	1.9941 mL	3.9883 mL	9.9707 mL
	10 mM	0.1994 mL	0.9971 mL	1.9941 mL	4.9853 mL
	15 mM	0.1329 mL	0.6647 mL	1.3294 mL	3.3236 mL
	20 mM	0.0997 mL	0.4985 mL	0.9971 mL	2.4927 mL
	25 mM	0.0798 mL	0.3988 mL	0.7977 mL	1.9941 mL
	30 mM	0.0665 mL	0.3324 mL	0.6647 mL	1.6618 mL
	40 mM	0.0499 mL	0.2493 mL	0.4985 mL	1.2463 mL
	50 mM	0.0399 mL	0.1994 mL	0.3988 mL	0.9971 mL
	60 mM	0.0332 mL	0.1662 mL	0.3324 mL	0.8309 mL
	80 mM	0.0249 mL	0.1246 mL	0.2493 mL	0.6232 mL
	100 mM	0.0199 mL	0.0997 mL	0.1994 mL	0.4985 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Adefovir dipivoxil142340-99-6GS 0840阿德福韦酯GS0840GS-0840HBVReverse TranscriptaseOrthopoxvirusEndogenous MetaboliteHepatitis B virusoralprodrugnucleotideanalogueinfectionInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Adefovir dipivoxil (Synonyms: 阿德福韦酯; GS 0840)

Customer Review

Other Forms of Adefovir dipivoxil:

MCE 顾客使用本产品发表的 1 篇科研文献

Adefovir dipivoxil 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Adefovir dipivoxil 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Adefovir dipivoxil (Synonyms: 阿德福韦酯; GS 0840)

Customer Review

Other Forms of Adefovir dipivoxil:

Adefovir dipivoxil 相关抗体

MCE 顾客使用本产品发表的 1 篇科研文献

Adefovir dipivoxil 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Adefovir dipivoxil 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z